Algipharma as

Fmc Biopolymer as

Arne Dessen

Philip Rye

Rolf Myrvold

Geir Klinkenberg

Edvar Onsoyen

David Thomas

Timothy Rutland Walsh

Bildad Nyambura

Håvard Sletta

Olav Gåserød

Paul Lewis

Elaine Ferguson

Anand Bakle

Katja Etel Hill

David William Thomas

Roy Ambli Dalmo

Edvar Onsøyen

Edvar Onsoeyen

Astrid Hilde Myrset

Timothy Walsh

Anne TØNDERVIK

A method of preparing spray dried particles for inhalation comprising providing: (i) an aqueous liquid composition including the alginate oligomer and an aqueous liquid composition including an anti-adherent compound, or (ii) an aqueous liquid composition including the alginate oligomer and an anti-adherent compound; providing an organic liquid composition including a phospholipid; combining a volume of the organic liquid composition with a volume of the aqueous liquid composition, wherein the total volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and wherein the total volume of aqueous liquid composition and said total volume of organic liquid composition are sufficient to provide a combination; homogenizing the combination to form an organic-in-aqueous liquid emulsion for spray drying; and spray drying the organic-in-aqueous liquid emulsion to form the spray dried particles for inhalation.

Inhalable powder formulations of alginate oligomers

The disclosure relates to an alginate oligomer of 2 to 75 monomer residues, wherein said monomer residues do not carry a sulphate group, for use as a blood anticoagulant in clinical and non-clinical applications, including in vivo, ex vivo and in vitro contexts. The invention further provides for the use of such an alginate oligomer in preparing a product or device having a reduced capacity to promote blood coagulation, wherein said alginate oligomer is provided at or on a surface of said product or device. Such products and devices form a further aspect of the invention.

Use of alginate oligomers as blood anticoagulants

The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject in need thereof. Also provided is an alginate oligomer for use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject and a product containing an alginate oligomer and further pharmaceutical for the treatment of intestinal microbial overgrowth and/or a CFTR modulator as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject.

Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract

Qualitative and quantitative methods are for the detection of alginate oligomers in body fluids based on analyzing the Fourier transform infrared spectroscopy (FTIR) spectrum of a body fluid sample, for example a sputum sample, at a specific wave number range and, more particularly, certain specific characteristic wavenumbers.

Method for the qualitative and quantitative detection of alginate oligomers in body fluids

A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.

Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction

The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.

Alginate oligomers for use in overcoming multidrug resistance in bacteria

The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of, said method comprising using said antibiotic together with an alginate oligomer. Themay be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with. In another aspect the method can be used to combatcontamination of a site e.g., for disinfection and cleaning purposes.

Treatment of Acinetobacter with alginate oligomers and antibiotics

An oral, immunostimulating material for mammals, birds, and reptiles comprising an immunostimulating amount of an alginate having a M content of at least 40% and an acceptable carriers.

Oral immunostimulation of mammals birds and reptiles from (1-4) linked &#x3b2;-D-mannuronic acid

An oral, immunostimulating material for mammals, birds, fish, and reptiles comprising an immunostimulating amount of an alginate having a M content of at least 40% and an acceptable carriers.

Growing community of inventors

Røyken, Norway

Arne Dessen